Rx Product News

NOVEMBER 11, 2013

Kazano
Marketed by: Takeda Pharmaceuticals America, Inc
Indication: The FDA has approved Kazano (alogliptin and metformin HCl)—a dipeptidyl-peptidase-4 inhibitor and biguanide combination product—as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (DM). Kazano is not indicated for treatment of type 1 DM or diabetic ketoacidosis. The starting dose should be individualized to the patient, but a maximum recommended daily dose of 25 mg alogliptin and 2000 mg metformin HCl should not be exceeded.
Dosage Form: Tablets (mg alogliptin/mg metformin HCl): 12.5/500, 12.5/1000
For More Information: www.takeda.us/products/default.aspx



Tivicay
Marketed by: ViiV Healthcare
Indication: The FDA has approved Tivicay (dolutegravir), an HIV-1 integrase strand transfer inhibitor (INSTI) indicated in combination with other antiretroviral agents for treating HIV-1 infection in adults and children 12 years and older and weighing at least 88 lb (40 kg). The recommended dose in treatment-naïve or treatment-experienced INSTI-naïve adults is 50 mg once daily. For pediatric dosing, see the prescribing information. Tivicay may be taken without regard to meals.
Dosage Form: Tablets: 50 mg
For More Information: www.viivhealthcare.com/our-medicines/tivicay.aspx



Valchlor
Marketed by: Ceptaris Therapeutics, Inc
Indication: The FDA has approved Valchlor (mechlorethamine), an alkylating drug indicated for the topical treatment of stages IA and IB mycosis fungoides–type cutaneous T-cell lymphoma in patients who have received prior skin-directed therapy. The recommended dose is once-daily application of a thin film to affected areas of the skin. Valchlor is for topical dermatologic use only.
Dosage Form: Gel: 0.016% w/w of mechlorethamine (equivalent to 0.02% mechlorethamine HCl) in 60-g tubes
For More Information: www.valchlor.com



Mirvaso
Marketed by: Galderma
Indication: The FDA has approved Mirvaso (brimonidine) topical gel, 0.33%, an alpha-adrenergic agonist for the topical treatment of persistent (nontransient) facial erythema of rosacea in adults 18 years or older. The recommended dose is application of a pea-size amount once daily to each of 5 areas of the face (ie, forehead, chin, nose, and each cheek) while avoiding the eyes and lips. Hands should be washed immediately after application.
Dosage Form: Gel, 0.33%: each gram contains 5 mg of brimonidine tartrate
For More Information: www.mirvaso.com

SHARE THIS SHARE THIS
0
 

In Seniors: Consider CMV Serostatus
When Recommending Flu Vaccine

Older people who have cytomegalovirus seem to have less robust responses to the trivalent influenza vaccine than those who do not have CMV.


 

 

Conference Coverage
News from the year's biggest meetings


Pharmacist Education
Clinical features with downloadable PDFs


 

SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.